Pfizer Inc

Most Recent

  • Pfizer COVID-19 vaccine
    News

    Will Pfizer’s COVID-19 Vaccine Protect Against the Omicron Variant?

    By Jennifer Farrington
  • Pfizer CEO Albert Bourla
    News

    Pfizer CEO Wasn't Arrested by the FBI—How the Rumor Started

    By Market Realist Team
  • Pfizer building in England
    News

    Pfizer's New COVID-19 Pill Plus HIV Drug Ritonavir Is 89% Effective Against Severe Illness

    By Robin Hill-Gray
  • Nurse giving someone a Pfizer COVID-19 vaccine
    Healthcare

    Only Certain People Are Eligible for Pfizer's COVID-19 Booster Shot

    By Ruchi Gupta
  • Pfizer COVID-19 vaccine
    News

    Who Is Exempt From COVID-19 Vaccine Mandate? Deadlines Approach

    By Kathryn Underwood
  • Nurse preparing a Pfizer COVID-19 vaccine
    News

    When Will COVID-19 Vaccine Boosters Be Available?

    By Rachel Curry
  • Young child getting vaccinated
    Healthcare

    How to Enroll a Child in a COVID-19 Vaccine Trial

    By Kathryn Underwood
  • Man looking at data and Pfizer logo
    Company & Industry Overviews

    Pfizer Paid the Largest Criminal Fine in U.S. History—Lawsuit Details

    By Danielle Letenyei
  • Person receiving COVID-19 vaccine
    News

    When Is Pfizer Booster Available? Fauci Gives COVID-19 Booster Update

    By Dan Clarendon
  • FDA sign
    News

    Does Pfizer Control the FDA Like Trump Claims? Short Answer, No

    By Danielle Letenyei
  • Bill Gates and Pfizer
    News

    Bill Gates Is an Advocate for COVID Vaccines, Doesn't Own Pfizer

    By Danielle Letenyei
  • Vaccine mandate sign in New York City restaurant
    Real Insights

    What Does Full FDA Approval Mean for Vaccines?

    By Rachel Curry
  • Trillium Therapeutics logo over Pfizer-branded hot air balloon
    Company & Industry Overviews

    Is TRIL a Buy After Pfizer Acquires Trillium Therapeutics?

    By Rachel Curry
  • best vaccine stock to buy
    Healthcare

    Best COVID-19 Vaccine Stocks to Buy Now for 2021

    By Ambrish Shah
  • have there been pfizer vaccine deaths
    Healthcare

    Is Pfizer’s COVID-19 Vaccine Safe and Effective?

    By Ambrish Shah
  • uploads///Article
    Company & Industry Overviews

    How Did AstraZeneca’s CVMD Franchise Perform in 2014?

    In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Animal Health Segment

    The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Major Developments for Johnson & Johnson in 3Q16

    Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]

    By Mike Benson
  • uploads///Pharma
    Earnings Report

    Johnson & Johnson’s Pharmaceuticals Segment Grows in 2Q15

    Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.

    By Mike Benson
  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

    Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

    By Daniel Collins
  • uploads///Spark pipeline
    Company & Industry Overviews

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.

    By Kenneth Smith
  • uploads///HIV
    Company & Industry Overviews

    Could Gilead Sciences’ Biktarvy Witness Solid Growth in 2018?

    In February 2018, the US FDA approved Gilead Sciences’ Biktarvy for the treatment of individuals with HIV-1 infection.

    By Daniel Collins
  • uploads///thermometer _
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive on Merck in September

    Of the 19 analysts tracking Merck (MRK) stock in September, four recommended a “strong buy” while ten analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Merck Expects Modest Revenue Growth in Fiscal 2016

    Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success

    On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.

    By Margaret Patrick
  • uploads///consumer health market
    Company & Industry Overviews

    Could Pfizer and P&G agree on a Consumer Health Business Deal?

    Pfizer (PFE) has been looking to sell its consumer health business since October 2017.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Recommend for Novartis in March 2018

    As discussed earlier, Novartis (NVS) reported EPS (earnings per share) of $1.21 on revenues of $12.9 billion during 4Q17.

    By Mike Benson
  • uploads///ISM
    Macroeconomic Analysis

    Expanding Service Sector Gives Relief to Economy in September

    With manufacturing slowing, a reading of the Non-Manufacturing Index at an above-neutral level (56.9) may provide some relief to the US economy, which is highly dependent on the service sector for its economic growth.

    By Lara Sheldon
  • uploads///GEVA ALXN LAL D
    Miscellaneous

    Backing Out of the Synageva BioPharma Deal, Part 3

    Things like acts of war and natural disasters aren’t MACS unless they disproportionately affect Synageva relative to other early-clinical-stage biopharmaceutical companies.

    By Brent Nyitray, CFA, MBA
  • uploads///Article
    Company & Industry Overviews

    Lilly’s Total Returns Are Lower than Some Pharma ETFs

    The total return for Lilly’s share price on the NYSE from July 2010 to June 2015 has been around 17.9%. This is lower than a few of the pharmaceutical ETFs.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Restricted Access Continues to Impact Praluent Sales in 2016

    Praluent is one of the Regeneron’s key new additions in the cardiovascular segment. It’s a PCSK9 therapy approved for lowering LDL cholesterol in patients.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Valuation Cheat Sheet

    On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Sanofi Increased Net Revenues in 2014

    Sanofi’s net revenues increased by ~2.5% to 33.8 billion euros in 2014, as compared to $23.2 billion in 2013.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Think about Bristol-Myers Squibb

    Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”

    By Margaret Patrick
  • uploads///Article
    Earnings Report

    Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15

    Novartis (NVS) posted its 2Q15 earnings on July 21, 2015. The company achieved adjusted EPS of $1.27 for 2Q15, ~7% lower than in 2Q14.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Teva Pharmaceutical in 2017

    Following the completion of its acquisition of Allergan’s Actavis Generics business on August 2, 2016, Teva Pharmaceutical plans to focus on realizing the deal’s synergies in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analyzing Pfizer’s Expense Projections for 2018

    Pfizer expects its 2018 R&D (research and development) expenses to be in the range of $7.7 billion–$8.1 billion.

    By Margaret Patrick
  • uploads///Pfizer revenues
    Company & Industry Overviews

    How Did Pfizer Perform in 3Q17?

    In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for Merck & Co. after 4Q17

    Merck & Co. (MRK) missed Wall Street analysts’ estimates for revenues but surpassed analysts’ estimates earnings per share.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings

    Pfizer recently rose by 2.7% on revenues of $13 billion for 1Q16, as compared to $10.9 billion in 1Q15, which represents a growth of 20% YoY.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Valuation Cheat Sheet for Fiscal 1Q16

    Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.

    By Mike Benson
  • uploads///ccdafbcfbddefdffcb
    Company & Industry Overviews

    Market Response to EMA Validation of Opdivo Application

    BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion Expected to Boost Keytruda’s 2017 Revenue

    On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).

    By Margaret Patrick
  • uploads///Eylea
    Earnings Report

    Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?

    Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US.

    By Jillian Dabney
  • uploads///close up _
    Earnings Report

    Pfizer Missed Analysts’ Third-Quarter Revenue Estimates

    Pfizer (PFE) released its third-quarter earnings on October 30.

    By Mike Benson
  • uploads///BHI HAL BHI basics
    Miscellaneous

    Baker Hughes basics

    Baker Hughes (BHI) is a leading supplier of oilfield services, products, technology, and systems to the worldwide oil and natural gas industry.

    By Brent Nyitray, CFA, MBA
  • uploads///Chart
    Earnings Report

    Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16

    AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

    By Mike Benson
  • uploads///Costs
    Earnings Report

    Bristol-Myers Squibb’s Profitability and Financial Guidance

    Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Could Expand Keytruda’s Revenues?

    In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.

    By Margaret Patrick
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Teva Stock Has Risen Significantly since November Lows: What’s Next?

    On January 5, 2018, Teva Pharmaceuticals (TEVA) closed at $19.2 per share, which was ~77% higher than its 52-week low of $10.8 reported on November 2, 2017.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Gardasil and What It Could Mean

    Total sales from Merck’s Gardasil during 3Q16 reached $860 million, a rise of ~38% over the $625 million in 3Q15.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Venclexta Witnessed Healthy Demand Trends in 1Q17

    AbbVie’s (ABBV) Venclexta was approved by the FDA on April 11, 2016. AbbVie has also successfully launched Venclexta in Germany and France.

    By Margaret Patrick
  • uploads///US dollar headwinds
    Macroeconomic Analysis

    The Strong Dollar Is Dragging Down US Companies’ Revenues

    As earnings reports and analyst call transcripts show, many of the companies reporting sales misses cited the strong dollar as a contributing factor.

    By Russ Koesterich, CFA
  • uploads///Analysts ratings
    Company & Industry Overviews

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

    By Daniel Collins
  • uploads///acquisition
    Company & Industry Overviews

    Medivation Is for Sale: How Much Should It Get?

    Considering the prospects for the pipeline, Medivation should get more than what Sanofi offered. It will probably get more than what Pharmacyclics received.

    By Jillian Dabney
  • pfizer
    Healthcare

    Where Is Pfizer's COVID-19 Vaccine Being Made?

    By Kathryn Underwood
  • uploads///xtandi market share
    Company & Industry Overviews

    How Xtandi Fueled Big Pharmaceutical Interest in Medivation

    Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Behind Amgen’s Plans to Penetrate the Migraine Segment

    Amgen and Novartis are exploring an investigational drug that is a CGRP antibody, AMG 334, for the treatment of episodic and chronic migraine headaches.

    By Margaret Patrick
  • uploads///Select Generic Pharma Companies Sales by Geo
    Healthcare

    What Are Biosimilars and Why Do They Benefit Generic Pharma?

    BUTCHER: Going back to what you said about generics being a cheaper alternative, why are they cheaper? DUFFY: The barriers to generic markets are usually a lot lower. If we look at the United States, back in 1984 they passed the Hatch-Waxman Act and essentially what this did was allow for an expedited approval process […]

    By VanEck
  • uploads///Currencies
    Earnings Report

    Dollar Appreciation Impacts IBM’s Growth in 2Q15

    IBM pointed to the strengthening US dollar for the decline in its revenues, which fell by 13.5% in fiscal 2Q15. On a constant currency basis, revenue only declined by 1%.

    By Anne Shields
  • uploads///Tracking error in the VNQ ETF tracking the RMZ Index
    Healthcare

    Comparing ETNs with ETFs: The must-know pros of ETNs

    ETNs are free of tracking errors, and investors can defer taxation until they mature or are sold.

    By Surbhi Jain
  • uploads///PE and share price
    Company & Industry Overviews

    Pfizer’s Medivation Acquisition: What You Need to Know

    On August 22, Medivation (MDVN) and Pfizer (PFE) entered into a definitive agreement. Pfizer will acquire Medivation for a consideration of ~$14 billion.

    By Jillian Dabney
  • uploads///XAL over
    Healthcare

    Merger must-knows: The shareholder vote and 90% tender condition

    Once the SEC approves the proxy, a vote is scheduled. Usually, the last condition for a deal is the vote of the target shareholders.

    By Brent Nyitray, CFA, MBA
  • uploads///PFE MDVN deal
    Company & Industry Overviews

    What’s the Story behind the Pfizer-Medivation Deal?

    Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    International Segment: Key Driver of VRX’s Revenue Growth in 2016

    In the first nine months of 2016, the Bausch + Lomb/International segment reported revenues of ~$3.4 billion, which equals year-over-year (or YoY) growth of ~0.4%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Eylea Could Face Tough Competition in 2016

    In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

    By Margaret Patrick
  • uploads///pill _
    Company & Industry Overviews

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.

    By Sarah Collins
  • uploads///Growth
    Earnings Report

    Johnson & Johnson’s 3Q15 Changes in Growth Rate

    Foreign exchange rates seem to have had a negative impact on Johnson & Johnson’s growth rate since ~50% of total revenues are reported from sales outside the US.

    By Mike Benson
  • uploads///euro _
    Company & Industry Overviews

    Why Amarin Is Soaring in First Half of January

    Amarin has been rising on rumors about pharmaceutical giant Pfizer (PFE) being interested in acquiring the company.

    By Margaret Patrick
  • uploads///Oncology
    Company & Industry Overviews

    A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta

    In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday

    Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.

    By Sarah Collins
  • uploads///MArket opportunity for Acthar
    Company & Industry Overviews

    Inside Mallinckrodt’s Major Valuation Catalysts

    Acthar is Mallinckrodt’s (MNK) leading product, and the company plans to achieve mid-single-digit to low-double-digit growth for the drug in fiscal 2016.

    By Jillian Dabney
  • uploads///dna _
    Earnings Report

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.

    By Sarah Collins
  • uploads///AGN PFE PFE basics
    Miscellaneous

    Allergan–Pfizer merger: What Does Pfizer Make besides Viagra?

    The Allergan–Pfizer merger will change Pfizer’s domicile to Dublin, Ireland, and allow them to gain access to overseas cash without a US repatriation tax.

    By Brent Nyitray, CFA, MBA
  • uploads///Chart
    Earnings Report

    What to Expect from Pfizer’s 2Q16 Earnings

    In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Amgen’s Nephrology Drugs Expect Falling Revenue in 4Q15

    Analysts projected a fall in the revenue for Amgen’s nephrology drugs, Aranesp and Epogen, in 4Q15. The drugs are expected to suffer in the coming quarters.

    By Margaret Patrick
  • uploads///strensiq
    Earnings Report

    Inside Alexion’s Metabolic Drugs Kanuma and Strensiq

    In 1Q16, Strensiq added $33.2 million to Alexion Pharmaceuticals’ top line. Now the drug is in its initial launch phase in the US, Germany, and Japan.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings

    Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s New Oncology Portfolio May See Healthy Growth

    In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.

    By Margaret Patrick
  • uploads///Eylea sales
    Earnings Report

    Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?

    Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.

    By Jillian Dabney
  • uploads///SLXP VRX SLXP basics
    Miscellaneous

    The Salix–Valeant merger: Basics of Salix Pharmaceuticals

    Xifaxin is by far Salix’s largest product, accounting for ~70% of its revenues in 2013. Xifaxin is a big reason for the Salix–Valeant merger transaction.

    By Brent Nyitray, CFA, MBA
  • uploads///ibrance
    Company & Industry Overviews

    Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer

    Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Understanding Bristol-Myers Squibb’s Other Segments

    Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Teva’s Granix Gets FDA Approval for Expanded Indication

    Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.

    By Sarah Collins
  • Healthcare

    Why AstraZeneca’s oncology pipeline is attractive to Pfizer

    Pfizer (PFE) is seeking to expand its oncology franchise and a combination with AstraZeneca (AZN) would be meaningful due to the latter’s pipeline of cancer drugs.

    By Samantha Nielson
  • uploads///PE ratio
    Earnings Report

    Key Factors That Impact Johnson & Johnson’s Forward Valuation

    Two factors expected to impact Johnson & Johnson’s forward valuation are increasing competition for Olysio and further decline in international revenues.

    By Nicole Sario
  • uploads///pina messina  unsplash
    Company & Industry Overviews

    Eli Lilly’s Valuation on May 17

    On May 17, Eli Lilly was trading at a forward PE multiple of 15.2x, which compares to the industry average of 13.6x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline Increases Top Line in 2Q16

    GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.

    By Mike Benson
  • How to Invest in Global Wide Moat Stocks
    Consumer

    How to Invest in Global Wide Moat Stocks

    The Morningstar Global Wide Moat Focus Index has global exposure, unlike the Morningstar International Moat Index (MOTI).

    By VanEck
  • uploads///Eylea
    Company & Industry Overviews

    How Regeneron Is Working to Maintain Eylea’s Dominance

    Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.

    By Jillian Dabney
  • uploads///pills medical money
    Company & Industry Overviews

    Why Pfizer’s Share Price Fell on November 20

    On November 20, Pfizer (PFE) closed at $43.53, which was 1.47% lower than its previous closing price.

    By Margaret Patrick
  • uploads///HUM AET downside
    Miscellaneous

    What Is the Risk-to-Reward Ratio of the Humana–Aetna Deal?

    Scenario analysis  In the risk-arbitrage world, a 12.2% expected return means a deal that has a lot of risk. Arbitrageurs sometimes refer to risk as “hair.” This deal is guaranteed a second request, and the regulators may simply be unable to get comfortable with the transaction, no matter what the companies offer in the way […]

    By Brent Nyitray, CFA, MBA
  • uploads///Van Eck Video
    Macroeconomic Analysis

    What Are Generic Drugs and Why Are They Important?

    TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]

    By VanEck
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?

    Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.

    By Mike Benson
  • uploads///RD
    Company & Industry Overviews

    What Were Pfizer’s Major Achievements in 2016?

    During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.

    By Jillian Dabney
  • uploads///SLXP VRX SLXP at a glance
    Miscellaneous

    Parsing the Salix–Valeant merger MAC clause: Part 1

    In the deal between Salix Pharmaceuticals and Valeant, the MAC clause lays out the circumstances under which Valeant can back out of its deal with Salix.

    By Brent Nyitray, CFA, MBA
  • uploads///SLXP VRX GI
    Miscellaneous

    Parsing the Salix–Valeant merger MAC clause: Part 2

    Pretty much anything that has a material adverse effect on the company will be considered a MAC, but there will be exceptions to that rule.

    By Brent Nyitray, CFA, MBA
  • uploads///PCYC ABBV ABBV basics
    Miscellaneous

    The Pharmacyclics–AbbVie Merger: The Basics of AbbVie

    A major reason for the Pharmacyclics–AbbVie merger is to diversify AbbVie away from its reliance on a single product, Humira, and boost its pipeline.

    By Brent Nyitray, CFA, MBA
  • uploads///specialty products pipeline
    Company & Industry Overviews

    Non-Opioid Pain Therapy Market Opportunity for Teva

    The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.

    By Sarah Collins
  • uploads///horizon as orphan drug company
    Company & Industry Overviews

    Buy Allows Horizon to Further Expand into Orphan Drug Space

    Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.

    By Jillian Dabney
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.